Products from BPS Bioscience require a minimum order value above 400€
Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It acts as an inhibitory co-receptor of the B-cell receptor to control the B-cell immune response. In 2017 the FDA approved Besponsa, an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.
Description: Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG32491.
Storage Stability: Room Temperature
Target: CD22
Uniprot: P20273
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Francesca Zammarchi, et al., 2024 Mol Cancer Ther. 23(4):520-531.